These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biological Response Modifiers Programme and cancer chemotherapy. Oldham RK Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193 [TBL] [Abstract][Full Text] [Related]
3. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
4. [Palliative therapy in cancer. 6. Quality of life and BRM therapy in cancer-patients]. Urushizaki I Gan To Kagaku Ryoho; 1990 Oct; 17(10):2119-29. PubMed ID: 1699499 [TBL] [Abstract][Full Text] [Related]
5. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
6. A clinical development paradigm for cancer vaccines and related biologics. Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G; J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079 [TBL] [Abstract][Full Text] [Related]
7. Design of clinical trials with biological response modifiers. Herberman RB Cancer Treat Rep; 1985 Oct; 69(10):1161-4. PubMed ID: 2412692 [TBL] [Abstract][Full Text] [Related]
8. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Royston P; Parmar MK; Qian W Stat Med; 2003 Jul; 22(14):2239-56. PubMed ID: 12854091 [TBL] [Abstract][Full Text] [Related]
9. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. Mazumdar M; Smith A; Schwartz LH J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836 [TBL] [Abstract][Full Text] [Related]
10. Is there a role for melatonin in supportive care? Lissoni P Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501 [TBL] [Abstract][Full Text] [Related]
11. Assessment of biological responses: what to measure and when. Maluish AE; Herberman RB Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356 [TBL] [Abstract][Full Text] [Related]
12. Criticism of tumor response criteria raises trial design questions. Twombly R J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740 [No Abstract] [Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
15. Modulation of antitumor immune responses by hematopoietic cytokines. Waller EK; Ernstoff MS Cancer; 2003 Apr; 97(7):1797-809. PubMed ID: 12655538 [TBL] [Abstract][Full Text] [Related]
16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
17. Improving the design of phase II trials of cytostatic anticancer agents. Stone A; Wheeler C; Barge A Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736 [TBL] [Abstract][Full Text] [Related]
18. Immunological monitoring and clinical trials of biological response modifiers. Baseler MW; Urba WJ Cancer Chemother Biol Response Modif; 1991; 12():231-50. PubMed ID: 1931445 [No Abstract] [Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]